PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 67 from 1 topic.Sort: Newest | Oldest
Tirzepatide in UK Digital Practice: Real-World Weight Loss at Scale
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low

Digital prescribing supports significant weight loss with tirzepatide.

THC:CBD Extract Modestly Eases Subjective MS Spasticity
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Also in Medication Safety

Antidiabetic drug safety profiles expand significantly post-marketing.

Dapagliflozin plus pioglitazone improves glycemia and hepatic steatosis markers
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Gastroenterology / Hepatology

Improved glycemic and liver outcomes found with combination therapy in T2DM.

Oral Orforglipron Added to Titrated Glargine Lowers HbA1c Without More Hypoglycemia
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate

ACHIEVE-5 gives pharmacists the first randomized data on an oral nonpeptide glucagon-like peptide 1 (GLP-1) receptor agonist layered onto titrated basal insulin in type 2 diabetes.

From Glucose-Centric to Outcomes-Driven: ADA 2026 Reshapes Diabetes Therapy
Reference Card Endocrinology / Diabetes / Obesity

How GLP-1 RAs and SGLT2 inhibitors displaced metformin as the default first-line in type 2 diabetes management.

GLP-1 Agonists Linked to Lower Antidepressant and Addiction Drug Starts
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Also in Psychiatry / Psychopharmacology

GLP-1RAs linked to reduced need for antidepressants and addiction medications.

Network Meta-Analysis Ranks Diabetes Drugs by Cardiovascular Benefit
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Cardiology

Diabetes drugs SGLT2i, GLP1RA, and tirzepatide cut cardiovascular events and mortality.

Perioperative Dapagliflozin Halves Postoperative AKI After Cardiac Surgery
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Moderate
Also in Perioperative / Anesthesia, Endocrinology / Diabetes / Obesity

Dapagliflozin cuts acute kidney injury risk post-cardiac surgery.

Oral Semaglutide Cuts Heavy Drinking but Misses Craving Endpoint
Analysis Behavioral Health / Addiction Medicine Hypothesis-generating Grade: Low
Also in Endocrinology / Diabetes / Obesity

Semaglutide potentially reduces heavy drinking in alcohol use disorder.

Balanced Crystalloids No Faster Than Saline for DKA Resolution
Analysis Critical Care / ICU Confirmatory Grade: Low
Also in Endocrinology / Diabetes / Obesity

No clear winner between balanced crystalloids and saline in DKA resuscitation.

Emerging Anti-Obesity Targets Extend Beyond Incretin Pharmacotherapy
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low

Innovative anti-obesity drugs offer hope beyond current treatments.

Empagliflozin Modestly Improves Liver Enzymes in MASLD, Not Lipids
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Also in Gastroenterology / Hepatology

Empagliflozin reduces liver enzymes in MASLD patients, showing promise.

Complementary SGLT2 Inhibitor Plus GLP-1 Agonist Therapy in Type 2 Diabetes
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate

Combining SGLT2is and GLP-1RAs may revolutionize diabetes management.

IDegLira Outperforms Glargine in One-Week Intensive Diabetes Therapy
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low

IDegLira outperforms insulin glargine for short-term diabetes control.

Combining SGLT2 Inhibitors and GLP-1 Agonists: Heart Failure Signal, Uncertain Evidence
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low

Combining the two classes lowered heart failure admissions but not MACE or major kidney events.